Figure 1: Four-day ex vivo expansion yields Th17 cells with potent antitumor efficacy.

A) TRP-1 Th17 cells were expanded from 12 hours to 14 days. B) ACT schematic. B16F10 tumors were established in mice from 7 days (tumor ~ 50mm²) to 12+ days (tumor ~ 140mm²). Animals were irradiated 5 Gy one day prior to ACT. C) Tumors established 7 days in mice were treated with Th17 cells. n=5-10 mice/group, representative of two experiments. D) Mice bearing B16F10 established 12 days were treated as in B) (n=10 mice/group, NT n=5). Representative of two experiments. E) Survival of mice treated in (D), combination of two experiments. n=22/group, n=17 NT. F-H) Human CD4⁺ T cells were polarized to Th17 phenotype and transduced with meso-CAR. F) Human M108 was inoculated 47 days pre-ACT. G) Waterfall plot relating tumor size 33 days post ACT to start. H) Serial measurements. n=8-9 mice/group, one experiment. Statistics: E) Log-rank test, *p<0.05, **p<0.01.